FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Discovery · preclinical After licensing a novel-target antibody, it is extending research into ADC candidates against the same and other new targets. Also seen: Early clinical · first deals

  • Said it would present research data on GENA-104 ADC, GENA-120 and GENB-120 at World ADC. Source

Roles often seen at this stageResearch & development · BD & licensing · Data & AI

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Genome & Company

Develops immuno-oncology antibodies and antibody-drug conjugates (ADCs) against novel targets found with its GNOCLE discovery platform.

GENA-104 ADC

Stage unconfirmed

An ADC directed at CNTN4, a novel target found with GNOCLE.

GENA-120 / GENB-120

Stage unconfirmed

GENA-120 is an ITGB4-targeted ADC; GENB-120 is a bispecific ADC targeting ITGB4 and TROP2.

GENA-104 (EP0089)

Stage unconfirmed

A CNTN4-targeted immuno-oncology antibody licensed to UK-based Ellipses Pharma in February 2025.

Announced

Announced it would present research data on its novel-target ADC pipeline and hold partnering meetings at World ADC San Diego.

Completion reported

Licensed the novel-target immuno-oncology candidate GENA-104 to Ellipses Pharma (UK).

Official role guide

Genome & Company careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 지놈앤컴퍼니, 월드 ADC'서 신규타깃 ADC 공개…글로벌 파트너링 추진 ↗한국경제 · Published 2026-09-15 · Sources checked 2026-11-18 · Original unavailable
  2. 지놈앤컴퍼니, 英 제약사에 면역항암제 후보물질 기술이전 ↗한국경제 · Published 2025-02-12 · Sources checked 2026-11-18 · Original unavailable